{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-023214","form_type":"8-K","ticker":"ALEC","cik":"0001653087","company_name":"Alector, Inc.","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.587465+00:00","generated_at":"2026-06-22T03:51:28.128617+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Alector Q3 2022 net loss $46.1M, cash $758.3M, pipeline advances","bullets":["Net loss of $46.1M ($0.56 loss per share); prior-year net income $126.6M ($1.56 EPS).","Collaboration revenue $14.9M, down from $182.4M YoY due to $173.4M GSK license in 2021.","Cash, cash equivalents and investments $758.3M; runway through 2024.","Enrolling Phase 3 INFRONT-3 (latozinemab for FTD-GRN) and Phase 2 INVOKE-2 (AL002 for early AD).","Initiated Phase 1 for AL044 (MS4A target for Alzheimer’s); IND for AL009 (immuno-oncology) expected Q4 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-023214","json":"https://secwatch.observer/filing/0000950170-22-023214.json","markdown":"https://secwatch.observer/filing/0000950170-22-023214.md","text":"https://secwatch.observer/filing/0000950170-22-023214.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1653087/000095017022023214/0000950170-22-023214-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1653087/000095017022023214/alec-20221108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T03:51:28.128617+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f03edd6e1336b203f89eb9efc671d57182756eb6","claim":"Alector, Inc. reported the quarter ended September 30, 2022 results: revenue $14.9 million.","evidence_excerpt":"research pipeline and helps drive business strategy. Third Quarter 2022 Financial Results Revenue. Collaboration revenue for the quarter ended September 30, 2022, was $14.9 million, compared to $182.4 million for the same period in 2021. The decrease of $167.6 mil","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1653087/000095017022023214/0000950170-22-023214-index.htm","confidence":0.8,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Revenue","value":"$14.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}